Bennett Pharma is only one of seventy-four 503B Manufacturing Facilities in the United States. The goal of the law is to increase patient safety. A 503B outsourcing facility is different than a traditional compound pharmacy because it is registered with the FDA, it is inspected by the FDA, it manufactures sterile drugs, it follows cGMP (current good manufacturing practices) and all products undergo rigorous testing.

As a 503B we can:

• compound any products on the bulk substance list

• produce any drugs on the drug shortage list

• sell for office stock (rather than single, prescriptions)

• provide needed medications to the medical, dental, and veterinary industries.

Bennett Pharmaceuticals is committed to significantly enhancing patient comfort through our superior proprietary topical anesthetics. We aim to set a new standard of patient care in both the medical and dental industries. By forging strategic partnerships, we will revolutionize pain management and transform patient experiences across the healthcare landscape.

Orlicaine and STAT have formulation and method patent protection that will provide 20 years exclusivity from the date of filing of the provisional patent application. As a 503B outsourcing facility Bennett manufactures Orlicaine and STAT as products and sells directly to doctors, clinics, hospitals, dentists, GPOs and DSOs (dental service organizations) at the wholesale level.

Bennett Pharma is committed to producing the highest quality compounded pharmaceuticals. All batches are produced according to cGMP and tested prior to release.

Establish a new, superior standard for patient comfort and care by enhancing clinicians' access to our high-quality, minimally invasive, injection-free, and non-opioid medications produced in our 503B Pharmacy according to cGMP.